WYSZOMIERSKI JACK L sold $198K of EXEL

WYSZOMIERSKI JACK L sold 3,925 shares of EXELIXIS, INC. (EXEL) at $50.55 ($0.20M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · WYSZOMIERSKI JACK L
Published Jun 3, 2026, 10:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 10:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EXEL
Neutral
medium confidence
Mentioned
$EXEL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

This provides incremental sentiment information but no new fundamental data (no trial, approval, guidance, or deal).

02

Market read

Use mainly for sentiment/positioning checks rather than as a standalone catalyst.

03

What to watch

The filing doesn’t indicate whether additional buys/sells occurred around the same period or whether the director’s plan size is routine versus unusual.

Relevance 6/10Novelty 3/10Timing: Filed June 3; transaction executed June 1 under a 10b5-1 plan.

Background

The article is an SEC Form 4 insider transaction disclosure (director selling shares).

Company-level read

Ticker impact

$EXELNeutralMedium confidence
Context

SEC Form 4 shows an EXELIXIS director sold 3,925 shares in an open-market transaction under a 10b5-1 plan on June 1.

Expected impact

Likely limited/short-lived impact; any reaction should be muted given the pre-arranged 10b5-1 plan.

Evidence & confidence

The filing is a routine insider transaction with a stated pre-arranged 10b5-1 plan, providing disclosure but not a new operating or clinical catalyst.

Market effects

Minimal—this is company-specific insider disclosure without sector-wide regulatory/clinical implications.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 sale, the market may overreact; price action could revert if no other catalysts exist.

Key entities

  • EXELIXIS, INC.

    Company whose director disclosed an open-market sale of shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EXELMedAI 8/10

Exelixis (EXEL) Q3 2026 Earnings Call Transcript

Exelixis reported Q3 2026 revenues of $659M, with cabozantinib franchise U.S. net product revenues at $605M, up 11% YoY. Global revenues reached $818M. Zanzalintinib is a key growth driver, with multiple trials advancing. GAAP net income was $218M ($0.88 per share). The company updated full-year guidance and repurchased $250M in stock.

$EXELMed

Exelixis Inc (EXEL) (Q3 2026) Earnings Call Highlights: CABOMETYX Momentum

Exelixis Inc (EXEL) reported Q3 2026 earnings, highlighting delays in zanzalintinib's PDUFA date to March 2027 and STELLAR-304 results to Q1 2027. Full-year 2026 revenue guidance was maintained but reflects reduced expectations due to temporal NET indication revenue. CABOMETYX sales grew 6% quarter-over-quarter, with gross-to-net deductions projected at 30%. The company addressed competition, clinical trials, and the 340B program's minimal impact.

$EXELMed

BMO raises Exelixis stock price target to $60 on OpEx outlook

BMO Capital raised Exelixis' (NASDAQ:EXEL) price target to $60 from $54, citing adjusted long-term operating expense assumptions. The stock trades near its 52-week high at $66.20, up 70% over the past year. Exelixis reported Q3 2026 earnings of $0.94 per share, beating estimates by 8.05%, with revenue of $658.69 million, a 1.81% beat. The company maintained its 2026 revenue guidance, attributing it to the gradual ramp of its NET product.